Pathogenic bacteria characteristics and drug resistance in acute, delayed, and chronic periprosthetic joint infection: A retrospective analysis of 202 patients.
antibiotics
drug-resistance
pathogens
periprosthetic joint infection
Journal
International wound journal
ISSN: 1742-481X
Titre abrégé: Int Wound J
Pays: England
ID NLM: 101230907
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
13
04
2023
received:
17
01
2023
accepted:
13
04
2023
medline:
18
9
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
ppublish
Résumé
To assist orthopaedic surgeons in choosing appropriate antibiotics, this study attempted to identify the common microorganisms that cause periprosthetic joint infection (PJI) and their respective drug resistance spectrums. The clinical data of 202 patients with PJI after primary hip and knee arthroplasty between January 2017 and December 2021 were retrospectively analysed. There were 84 males and 118 females, aged (63.03 ± 13.10) years (range: 24-89 years). A total of 102 and 100 patients underwent total hip and total knee arthroplasty, respectively. Based on the time of postoperative infection, the patients were divided into acute (25 cases), delayed (91 cases), and chronic (86 cases) PJI groups. The results of pathogen species, composition ratio, and drug susceptibility tests were collected. Gram-positive bacteria were the primary causative pathogens of PJI (58.91%, 119/202), and their culture-positive rates in patients with acute, delayed, and chronic PJI were 32.00% (8/25), 62.64% (57/91), and 62.79% (54/86), respectively. Staphylococcus epidermidis and Staphylococcus aureus were the major gram-positive bacteria detected, followed by gram-negative bacteria (29/202, 14.36%), and fungi (4/202, 1.98%). Gram-positive bacteria showed higher resistance to penicillin (81.25%), oxacillin (63.33%), erythromycin (61.17%), and clindamycin (48.35%) and 100% sensitivity to linezolid, vancomycin, daptomycin, and tigecycline. In gram-negative bacteria, the drug resistance rates to cefazolin, gentamicin, furantoin, cefuroxime, ticacillin/clavulanic acid, ceftriaxone, ciprofloxacin, and tobramycin were >50%. However, no vancomycin-resistant bacteria were discovered in the current study. The drug resistance rate to carbapenems was low, ranging from 0% to 3.57%. Gram-positive bacteria are the main causative pathogens of PJI, and the resistance rate of pathogens of chronic PJI is higher than those of delayed and acute PJI. Use of cefuroxime and clindamycin in patients with PJIs should proceed with caution because of the high drug resistance rate. Vancomycin can be used as a first-line antibiotic against gram-positive bacteria. Carbapenems can be used as the first choice against gram-negative bacteria because of to their high sensitivity.
Identifiants
pubmed: 37186450
doi: 10.1111/iwj.14212
pmc: PMC10502290
doi:
Substances chimiques
Clindamycin
3U02EL437C
Cefuroxime
O1R9FJ93ED
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3315-3323Subventions
Organisme : Natural Science Foundation of Shaanxi Province
ID : 2020JQ-962
Informations de copyright
© 2023 The Authors. International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Références
Clin Infect Dis. 2009 Oct 1;49(7):1036-43
pubmed: 19691430
N Engl J Med. 2004 Oct 14;351(16):1645-54
pubmed: 15483283
J Arthroplasty. 2018 May;33(5):1309-1314.e2
pubmed: 29551303
Knee Surg Sports Traumatol Arthrosc. 2016 Oct;24(10):3080-3087
pubmed: 25829328
Instr Course Lect. 2016;65:467-75
pubmed: 27049212
J Arthroplasty. 2021 May;36(5):1484-1489.e3
pubmed: 33422392
Clin Orthop Relat Res. 2022 Aug 1;480(8):1491-1500
pubmed: 35420556
J Clin Microbiol. 2022 Jun 15;60(6):e0219621
pubmed: 35264020
Sci Rep. 2022 Oct 31;12(1):18319
pubmed: 36316456
Clin Microbiol Infect. 2019 Jul;25(7):845-850
pubmed: 30678837
Diagn Microbiol Infect Dis. 2019 Jul;94(3):255-259
pubmed: 30738691
J Arthroplasty. 2017 Sep;32(9):2663-2668
pubmed: 28456561
Clin Orthop Relat Res. 2015 Jul;473(7):2283-90
pubmed: 25690169
Bone Joint J. 2019 May;101-B(5):582-588
pubmed: 31039037
Infect Dis Clin North Am. 2017 Jun;31(2):237-252
pubmed: 28366224
Semin Immunopathol. 2011 May;33(3):295-306
pubmed: 21603890
J Arthroplasty. 2017 Mar;32(3):933-947
pubmed: 27789094
Knee Surg Relat Res. 2017 Sep 1;29(3):155-164
pubmed: 28854760
Adv Exp Med Biol. 2015;830:29-46
pubmed: 25366219
Future Microbiol. 2011 Nov;6(11):1329-49
pubmed: 22082292
J Arthroplasty. 2011 Dec;26(8):1136-8
pubmed: 22075161
Bone Joint J. 2015 Aug;97-B(8):1076-81
pubmed: 26224824
Int Wound J. 2023 Oct;20(8):3315-3323
pubmed: 37186450
Int Orthop. 2016 Jul;40(7):1367-73
pubmed: 26183140
Clin Microbiol Infect. 2019 Aug;25(8):1021-1025
pubmed: 30625412
J Infect. 2021 Nov;83(5):542-549
pubmed: 34509512
J Infect Public Health. 2020 Dec;13(12):1888-1891
pubmed: 33289642
Expert Rev Anti Infect Ther. 2013 Apr;11(4):395-409
pubmed: 23566149